600252.SH
中恒集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 2.18
−1.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.7B | 2.1B | 3.0B | 2.7B |
| Cost of Revenue | 841.6M | 977.5M | 1.1B | 1.1B | 1.1B |
| Gross Profit | 740.3M | 771.0M | 981.2M | 1.9B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 121.1M | 125.3M | 117.5M | 153.7M | 134.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 338.6M | 342.7M | 349.3M | 381.0M | 324.2M |
| Selling & Marketing Expense | 494.1M | 491.6M | 666.2M | 1.3B | 1.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 962.4M | 957.9M | 1.1B | 1.8B | 1.6B |
| Cost and Expenses | 1.8B | 1.9B | 2.3B | 2.9B | 2.7B |
| Operating Income (EBIT) | (570.4M) | (518.3M) | (517.1M) | 132.7M | 43.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (583.6M) | (527.1M) | (508.3M) | 82.7M | 63.8M |
| Income Tax Expense | (37.4M) | (31.8M) | 42.7M | 52.2M | 51.4M |
| Bottom Line | |||||
| Net Income | (408.0M) | (357.1M) | (377.0M) | 84.3M | 79.0M |
| Earnings from Cont. Ops | (546.2M) | (495.3M) | (551.0M) | 30.5M | 12.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (408.0M) | (357.1M) | (377.0M) | 84.3M | 79.0M |
| Per Share | |||||
| Basic EPS | (CN¥0.13) | (CN¥0.11) | (CN¥0.11) | CN¥0.02 | CN¥0.02 |
| Diluted EPS | (CN¥0.13) | (CN¥0.11) | (CN¥0.11) | CN¥0.02 | CN¥0.02 |
| Revenue Per Share | CN¥0.50 | CN¥0.56 | CN¥0.62 | CN¥0.87 | CN¥0.79 |
| Shares | |||||
| Basic Shares Outstanding | 3.2B | 3.1B | 3.4B | 3.4B | 3.4B |
| Diluted Shares Outstanding | 3.2B | 3.1B | 3.4B | 3.4B | 3.4B |
| Profitability Metrics | |||||
| EBITDA | — | (361.3M) | (349.9M) | 325.4M | 230.6M |
| D&A | — | 157.0M | 167.2M | 192.7M | 187.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026